ClinicalTrials.gg
CompletedNCT03303066Updated May 3, 2023

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

A Phase 2/3 interventional study of FG-4592 and Placebo in Anemia and Myelodysplastic Syndrome, sponsored by FibroGen. Completed at 38 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by FibroGen · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
38th of 43
43 · median 154
Started
2018
with 1 other
Phase 2/3
Only one
of the 43
Registered
26th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 38th largest by enrollment, is one of 2 that started in 2018, is the only one in phase 2/3, and was the 26th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The objective of this study to evaluate the efficacy FG-4592 for the treatment of anemia in Chinese participants with lower risk MDS.

Read the detailed description

This is a Phase 2/3 trial with sequential Phase 2 and Phase 3 components. In each part, there is an up to 4 weeks screening period followed by a treatment period of 26 weeks and a 4 week follow-up period.

03

Conditions studied

  • Anemia
  • Myelodysplastic Syndrome

Keywords

  • Myelodysplastic Syndromes
  • Anemia
  • Hemoglobin (Hb)
  • Low Risk Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of primary MDS classified as very low, low or intermediate risk with \<5% blasts (documented within 12 weeks prior to Day 1)
  • Screening \<10 g/dL and ≥6g/dL
  • Transfusion independent defined as no red blood cell transfusions within 12 weeks of Day 1
  • Erythropoiesis-stimulating agent (ESA)-naïve (not within 30 days of Day 1)
  • (ECOG) performance status 0, 1, or 2

Key Exclusion Criteria:

  • Diagnosis of secondary MDS
  • Significant myelofibrosis (>2+fibrosis)
  • Prior therapy with azacitidine, decitabine, antithymocyte globulin, cyclosporine, thalidomide, or lenalidomide within 12 weeks prior to Day 1
  • Baseline erythropoietin level of >400 units (U)/liter (L)
  • anemia due to non-MDS etiologies

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Phase 2 Part: FG-4592

    Fixed starting doses (different doses for lower body weight \& higher body weight) of FG-4592 administered orally 3 times a week (TIW) for up to 26 weeks; dose adjustments to Hb levels are allowed during the study.

    Drug: FG-4592

  • Experimental
    Phase 3 Part: FG-4592

    Fixed starting doses (different doses for lower body weight \& higher body weight) of FG-4592 administered orally TIW for up to 26 weeks; dose adjustments to Hb levels are allowed during the study.

    Drug: FG-4592

  • Placebo comparator
    Phase 3 Part: Placebo

    Placebo (matching to FG-4592) administered orally TIW for up to 26 weeks.

    Drug: Placebo

Interventions

  • Oral

    Also known as: Roxadustat, AZD9941

  • DrugPlacebo

    Oral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Hemoglobin (Hb) Response to FG-4592 Without Transfusion

    Hemoglobin response to FG-4592 is defined as an increase in mean Hb of ≥1.0 grams (g)/deciliter (dL) from baseline within any 8-week period during the study without transfusion.

    Time frame: 26 weeks

Secondary outcomes

  1. Number of Participants With Hb Increase ≥1.0 g/dL From Baseline

    Hb response to FG-4592 is defined as an increase in mean Hb of ≥1.0 g/dL from baseline within any 8-week period during the study without transfusion.

    Time frame: 26 weeks

  2. Time to First Hb Response

    Hb response to FG-4592 is defined as an increase in mean Hb of ≥1.0 g/dL from baseline within any 8-week period during the study without transfusion.

    Time frame: 26 weeks

  3. Change From Baseline in Mean Hb in Weeks 25 to 27

    Time frame: Baseline, Weeks 25 to 27

  4. Percentage of Participants With Mean Hb ≥10.0 g/dL Within Any 8-week Period During the Study Without Transfusion

    Time frame: 26 weeks

  5. Number of Participants that Require Transfusions or Hb <6 g/dL up to Week 27

    Time frame: Up to Week 27

  6. Mean Change From Baseline in Functional Assessment of Cancer Therapy - Anemia (FACT-An) and Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores at Week 27

    Frame: Baseline, Week 27

    Time frame: 30 weeks

07

Study locations

38 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • Anhui Provincial Hospital
    Hefei, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • China-Japan Friendship Hospital
    Beijing, Beijing, China
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
  • Peking University First Hospital
    Beijing, Beijing, China
  • Peking University Third Hospital
    Beijing, Beijing, China
  • Xiyuan Hospital, CACMS
    Beijing, Beijing, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu, China
  • Guangdong General Hospital
    Guangzhou, Guangdong, China
  • Nan Fang Hospital
    Guangzhou, Guangdong, China
  • Zhuzhou Central Hospital
    Zhuzhou, Guangdong, China
  • Hainan Central Hospital
    Haikou, Hainan, China
  • Second hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Tumor Hospital of Henan province
    Zhengzhou, Henan, China
  • Tongji Hospital, Tongji Medical College of HUST
    Wuhan, Hubei, China
  • Union Hospital Affiliated Tongji Medical College Huazhong University of Science and Technolog
    Wuhan, Hubei, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital Of Soochow University
    Suzhou, Jiangsu, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu, China
  • Affiliated Hospital of Shandong University of Traditional Chinese Medicine
    Jinan, Shandong, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • The Affiliated Hospital of Xuzhou Medical University
    Jinan, Shandong, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai, China
  • Shanghai Tongji Hospital
    Shanghai, Shanghai, China
  • Shaanxi Provincial People's Hospital
    Xian, Shanxi, China
  • The First Affiliated Hospital of Xi'an Jiao Tong University Medical College
    Xian, Shanxi, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
  • Blood disease hospital of Chinese Academy of Medical Sciences
    Tianjin, Tianjin, China
  • The Second Hospital of Tianjin Medical University
    Tianjin, Tianjin, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • The First Affiliated Hospital, Zhejiang University Medical College
    Hangzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Jan 2023, 55 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2017
First posted
Oct 5, 2017
StartActual
Jun 6, 2018
Primary completionActual
Jan 11, 2023
CompletionActual
Feb 8, 2023
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03303066
Lead sponsor
FibroGen
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Oct 5, 2017
Start date
Jun 6, 2018
Primary completion
Jan 11, 2023
Completion
Feb 8, 2023
Last update
May 3, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion